Stem Cell Therapy: The Complete Evidence-Based Guide

Somewhere in your body right now, stem cells are quietly doing their job. They’re replacing dead skin cells, replenishing your blood supply, and repairing small injuries you don’t even notice. This natural repair system is the foundation of one of the most talked-about (and most misunderstood) areas of modern medicine: stem cell therapy.

The idea is simple enough. If your body already uses stem cells to heal itself, what happens when you concentrate those cells and deliver them directly to a damaged joint, a degenerating disc, or an injured tendon? That question has launched thousands of research studies, hundreds of clinics, and no small amount of controversy. Some providers promise miraculous results. Skeptics dismiss the entire field as hype. The truth, as you might expect, sits somewhere in between.

This guide cuts through the noise. You’ll learn what stem cells actually are, which conditions have real evidence behind them, what the treatment process looks like, what it costs, and how to tell a qualified provider from one selling false hope. Whether you’re weighing stem cell therapy for a bum knee or just trying to understand what all the fuss is about, you’ll find straight answers here, grounded in peer-reviewed science.

What Are Stem Cells?

Stem cells are undifferentiated cells with two defining abilities: they can renew themselves through cell division, and they can develop into specialized cell types [1]. Think of them as your body’s raw materials. Unlike a muscle cell or a nerve cell, which can only be one thing, a stem cell hasn’t yet committed to a specific identity.

Not all stem cells are created equal. There are several types, each with different capabilities and different implications for therapy.

Embryonic Stem Cells (ESCs)

Embryonic stem cells come from early-stage embryos (typically 3 to 5 days old) and are considered “pluripotent,” meaning they can become virtually any cell type in the body. While they’re powerful research tools, their use in therapy remains limited due to ethical debates and the risk of tumor formation. You won’t encounter ESCs at a regenerative medicine clinic.

Adult Stem Cells (Mesenchymal Stem/Stromal Cells)

These are the workhorses of clinical stem cell therapy. Mesenchymal stem cells (MSCs) were first characterized in 1999 when researchers demonstrated their ability to differentiate into bone, cartilage, and fat cells under laboratory conditions [1]. Since then, a growing body of research has shown that MSCs do far more than just turn into new tissue. They secrete growth factors, modulate the immune system, and reduce inflammation [3].

It’s worth noting that the name itself is evolving. Dr. Arnold Caplan, who originally coined the term “mesenchymal stem cells,” later argued that they should be called “medicinal signaling cells” because their primary therapeutic benefit comes from the chemical signals they release, not from transforming into new tissue [2]. The International Society for Cell & Gene Therapy has established minimum criteria for defining these cells, including specific surface markers and the ability to differentiate into bone, fat, and cartilage in the lab [8].

Induced Pluripotent Stem Cells (iPSCs)

iPSCs are adult cells that have been genetically reprogrammed back to a stem-cell-like state. They hold enormous promise for personalized medicine because they can be created from a patient’s own skin or blood cells. However, iPSC-based therapies are still largely in the research phase and aren’t widely available in clinical practice.

Sources of Stem Cells Used in Therapy

The stem cells used in clinical treatments today come from several sources, each with its own profile of advantages and limitations:

Bone Marrow: The traditional gold standard. Bone marrow aspirate concentrate (BMAC) is harvested from your iliac crest (the back of the hip bone) and processed to concentrate the stem cells and growth factors. Studies by Centeno and colleagues used this approach to demonstrate cartilage volume increases in patients with degenerative joint disease [5]. Bone marrow yields a reliable population of MSCs along with other regenerative cells.

Adipose (Fat) Tissue: Fat harvested through a mini-liposuction procedure contains a large number of stromal vascular fraction (SVF) cells, which include MSCs. Research by Koh and colleagues showed clinical improvements and cartilage preservation when adipose-derived stem cells were injected into osteoarthritic knees [7]. Fat-derived cells are abundant and relatively easy to obtain.

Umbilical Cord Blood and Tissue: Donated from healthy births, umbilical cord products contain young, vigorous cells. Wharton’s jelly, the connective tissue within the umbilical cord, is particularly rich in MSCs. These are allogeneic (from a donor), which means no harvesting procedure for the patient but also means you’re receiving someone else’s cells.

Peripheral Blood: After stimulation with certain growth factors, stem cells can be mobilized into the bloodstream and collected. This approach is more common in hematologic (blood-related) applications than in orthopedic or regenerative medicine.

How Stem Cell Therapy Works

If you picture stem cells simply replacing damaged tissue cell-for-cell, you’re only seeing a small part of the picture. The current understanding of how MSC-based therapies work is considerably more nuanced [2][3].

Paracrine Signaling

The primary mechanism behind MSC therapy appears to be paracrine signaling: the stem cells release a cocktail of bioactive molecules, including growth factors, cytokines, and extracellular vesicles (exosomes), that influence surrounding cells [2][3]. These signals can:

• Reduce inflammation at the site of injury
• Recruit the body’s own repair cells to the area
• Inhibit cell death (apoptosis) in damaged tissue
• Stimulate new blood vessel formation (angiogenesis)
• Promote tissue-specific regeneration

This is why Dr. Caplan pushed for the name change to “medicinal signaling cells.” The cells function more like a pharmacy than a building crew [2].

Immunomodulation

MSCs have a remarkable ability to calm overactive immune responses. They interact with T cells, B cells, natural killer cells, and dendritic cells, turning down inflammatory signaling pathways [3]. This property makes them especially interesting for autoimmune conditions, transplant medicine, and any disease driven by chronic inflammation.

Differentiation

Under the right conditions, MSCs can differentiate into bone cells (osteoblasts), cartilage cells (chondrocytes), and fat cells (adipocytes) [1][8]. Whether this happens to a meaningful degree after injection into a living patient is still debated. Most researchers now believe that differentiation plays a smaller role than paracrine effects in the clinical outcomes we see [2][9].

Delivery Methods

How stem cells reach the target tissue matters. Common delivery approaches include:

• Direct injection: Ultrasound-guided or fluoroscopy-guided stem cell injections place cells precisely at the site of damage. This is the standard for joint, tendon, and spine treatments.
• Intravenous (IV) infusion: Cells are delivered through the bloodstream and home in on areas of inflammation. This approach is more common for systemic conditions like autoimmune diseases.
• Surgical implantation: During an open or arthroscopic procedure, cells can be applied directly to the tissue. Hernigou and colleagues used this method to augment rotator cuff repairs [11].
• Scaffolds: Cells can be seeded onto biocompatible materials that provide structure and slowly release the cells at the treatment site.

Conditions Treated with Stem Cell Therapy

Stem cell therapy is being studied and applied across a wide range of medical conditions. The strength of the evidence varies enormously from one condition to the next. Here’s an honest assessment of where things stand.

Orthopedic Conditions

This is where stem cell therapy has the most clinical data and the longest track record.

Knee Osteoarthritis: The strongest evidence for stem cell therapy exists for knee osteoarthritis. Jo and colleagues published a dose-escalation trial showing that high-dose MSC injections produced significant improvements in pain and function, along with signs of cartilage regeneration on MRI, in patients with knee OA [4]. A randomized controlled trial by Vega and colleagues compared allogeneic bone marrow MSCs to hyaluronic acid and found superior outcomes in the stem cell group [6]. A systematic review in the British Journal of Sports Medicine confirmed that the evidence, while promising, still needs larger, longer-term trials [12].

Rotator Cuff Injuries: Hernigou and colleagues demonstrated that adding bone marrow-derived MSCs to rotator cuff repairs improved healing rates and reduced re-tear rates compared to repair alone [11]. This is a growing area of research, with evidence that stem cells may be most useful as an adjunct to surgical repair rather than a standalone treatment.

Degenerative Disc Disease: Early studies show potential for intradiscal MSC injections to reduce pain and slow disc degeneration [13]. However, the evidence base is still small, consisting mostly of case series and small pilot trials. If you’re dealing with chronic back pain, stem cells are an option worth discussing with a specialist, but expectations should be tempered.

Tendon Injuries: Lateral epicondylitis (tennis elbow), Achilles tendinopathy, and patellar tendinopathy have all been treated with stem cell and PRP-based approaches. Results are encouraging but mostly limited to case series and small comparative studies.

Neurological Conditions

Multiple Sclerosis and Other Autoimmune Neurological Diseases: MSCs’ immunomodulatory properties make them a candidate for conditions like MS. Phase I and II clinical trials have demonstrated safety and some signals of efficacy, including stabilization of disability progression and reductions in inflammatory markers [14]. Larger trials are underway but results are preliminary.

Spinal Cord Injury: Preclinical data is extensive, and early-phase clinical trials have shown that MSC transplantation is safe. Functional improvements have been modest and inconsistent [15]. This remains an area of active research rather than an established therapy.

Stroke and Traumatic Brain Injury: Several clinical trials are examining MSC infusions for stroke recovery. Early results suggest potential improvements in neurological function, but the data is too early to draw firm conclusions [15].

Autoimmune Conditions

The immunomodulatory properties of MSCs [3] have spurred research into conditions like rheumatoid arthritis, systemic lupus erythematosus, Crohn’s disease, and graft-versus-host disease (GVHD). The strongest autoimmune evidence may be in GVHD, where MSC infusions have shown meaningful response rates in steroid-refractory cases [16]. For other autoimmune conditions, the evidence remains in early clinical trial phases.

Cardiac Conditions

Heart Failure and Post-Myocardial Infarction: Numerous clinical trials have investigated MSC therapy for heart disease. A meta-analysis of randomized trials found modest improvements in left ventricular ejection fraction and reductions in infarct size, though the clinical significance of these improvements is still debated [17]. Cardiac stem cell therapy is one of the most actively researched areas, with several large trials completed or in progress.

Aesthetic and Hair Loss Applications

Stem cell therapy for hair loss is a newer application that has gained significant patient interest. The approach typically involves injecting SVF or MSC-derived growth factors into the scalp to stimulate dormant hair follicles. Early studies show increased hair density and thickness in patients with androgenetic alopecia [18]. The evidence is still limited to small trials, but results are encouraging, particularly when combined with PRP therapy.

Erectile Dysfunction

Preclinical studies and early clinical trials suggest that stem cell therapy may help restore erectile function by promoting nerve regeneration and improving blood flow. Most published data comes from animal models and small human pilot studies, making this a speculative application at this stage.

What the Research Actually Shows

It’s tempting to either dismiss stem cell therapy as pure hype or embrace it as a miracle cure. Neither position holds up under scrutiny. Here’s what the evidence actually tells us.

Strong Evidence

Knee osteoarthritis has the most convincing data. Multiple randomized controlled trials have demonstrated that MSC injections can reduce pain, improve function, and show signs of cartilage protection or regeneration on imaging [4][6]. The systematic review by Pas and colleagues in BJSM analyzed the available RCTs and found a positive trend, while also noting significant variability in cell sources, doses, and outcome measures across studies [12]. The evidence is strong enough that many sports medicine and orthopedic specialists now consider stem cell therapy a reasonable option for patients who have failed conservative treatments but want to avoid or delay joint replacement.

Moderate Evidence

Rotator cuff augmentation has solid support from comparative studies like Hernigou’s work [11], though large RCTs are still needed. Cardiac applications have enough trial data to suggest a real but modest benefit. GVHD has regulatory approval in some countries (Japan, Canada, parts of Europe) based on clinical trial evidence [16].

Preliminary or Emerging Evidence

Neurological conditions (MS, spinal cord injury, stroke), other autoimmune diseases, degenerative disc disease, hair restoration, and erectile dysfunction all have early-phase data that ranges from promising to inconclusive. These are areas where reasonable clinicians may offer treatment on a case-by-case basis, but patients should understand they’re at the frontier of medicine, not on well-established ground.

Key Limitations in the Current Research

Honestly evaluating the stem cell therapy literature means acknowledging several recurring problems [9][10][12]:

• Lack of standardization: Different studies use different cell sources, cell counts, processing methods, and delivery techniques. Mautner and colleagues have called for a standard classification system for biologic treatments to make studies comparable [10].
• Small sample sizes: Many positive studies involve fewer than 50 patients.
• Short follow-up periods: Most studies track patients for one to two years. We need five- and ten-year data.
• Placebo response: Joint injections carry a significant placebo effect. Some improvements attributed to stem cells may reflect this.
• Publication bias: Positive results get published more easily than negative ones.
• Variable cell quality: The number, viability, and potency of MSCs can vary dramatically between patients and processing methods [9].

None of these limitations mean stem cell therapy doesn’t work. They mean we need to be careful about overstating what we know. The field is moving quickly, and the evidence base is growing every year.

The Stem Cell Therapy Procedure

If you decide to move forward with stem cell therapy, here’s what the process typically looks like from start to finish.

Initial Consultation and Evaluation

A qualified provider will begin with a thorough evaluation: medical history, physical examination, imaging review (X-rays, MRI), and a discussion of your treatment goals. Not every patient is a good candidate. Factors like the severity of your condition, your overall health, medications you take (particularly blood thinners and certain anti-inflammatory drugs), and your expectations all influence whether stem cell therapy makes sense for you.

Cell Harvesting (for Autologous Procedures)

If you’re receiving your own cells, the harvesting step comes first.

Bone Marrow Aspiration: You’ll lie face down while the area over your posterior iliac crest is numbed with local anesthetic. A special needle is inserted into the bone, and marrow is aspirated. Most patients describe it as a deep pressure or aching sensation rather than sharp pain. The procedure takes about 15 to 30 minutes. The aspirate is then placed in a centrifuge to concentrate the stem cells and growth factors into BMAC.

Adipose Tissue Harvesting: A small area (often the abdomen or flank) is numbed, and fat is collected through a mini-liposuction procedure using a thin cannula. The fat is then processed to isolate the stromal vascular fraction. This takes roughly 30 to 45 minutes.

For allogeneic (donor-derived) products, such as umbilical cord tissue or Wharton’s jelly preparations, there’s no harvesting step for the patient. The product arrives pre-prepared and is thawed or reconstituted before injection.

Processing

The harvested tissue is processed in the clinic or a nearby laboratory, typically using a centrifuge and sometimes enzymatic digestion (for adipose tissue). Processing time ranges from 15 minutes to about an hour. The goal is to concentrate the regenerative cells while removing red blood cells and other non-therapeutic components.

Injection or Delivery

For orthopedic applications, the concentrated cells are injected directly into the target tissue under ultrasound or fluoroscopic guidance. Precision matters here: placing cells accurately at the site of damage improves outcomes. The injection itself takes only a few minutes.

For systemic conditions, cells may be delivered intravenously. For surgical augmentation, they’re applied during the operative procedure.

Recovery Timeline

Recovery varies by condition and delivery method, but a general timeline for orthopedic stem cell injections looks like this:

• Days 1 to 3: Mild to moderate soreness and swelling at the injection site. Rest and ice are recommended. Avoid anti-inflammatory medications (NSAIDs), as they can interfere with the inflammatory cascade that stem cells need to do their work.
• Weeks 1 to 4: Gradual return to light activity. Physical therapy typically begins within the first two weeks.
• Months 1 to 3: Incremental improvement in pain and function. Many patients notice the most dramatic changes during this window.
• Months 3 to 12: Continued remodeling and healing. Some studies show improvements continuing for up to a year after injection [4][5].

Most patients can return to desk work within a day or two and resume light exercise within two to four weeks.

Risks, Side Effects, and Red Flags

Stem cell therapy, when performed by a qualified provider using evidence-based protocols, has a generally favorable safety profile. But no medical procedure is without risk, and the stem cell field has some unique concerns.

Common Side Effects

• Pain and swelling at the injection or harvest site (nearly universal, typically resolving within a few days)
• Bruising at the harvest site (especially with bone marrow aspiration or liposuction)
• Temporary increase in joint stiffness
• Mild fatigue for a day or two after the procedure

Serious but Rare Risks

• Infection at the injection or harvest site
• Nerve or blood vessel damage during injection (minimized with image guidance)
• Allergic or immune reaction (more relevant with allogeneic/donor products)
• Failure of the treatment to produce meaningful improvement

Risks Specific to Unregulated Products

This is where caution becomes critical. The FDA regulates stem cell products as biologics, and the agency has taken enforcement action against clinics marketing unapproved stem cell treatments [19]. Under current FDA guidelines (21 CFR Part 1271), autologous cells that are minimally manipulated and used for homologous purposes (same basic function) are generally exempt from the full biologics approval process. Cells that are more than minimally manipulated, or used for non-homologous purposes, require an IND (Investigational New Drug) application and FDA approval.

Many clinics operate in a gray area, and some clearly outside the law. Reports of serious adverse events from unregulated stem cell clinics include blindness from unproven retinal injections, infections from contaminated products, and tumor formation from improperly processed cells [19].

Red Flags to Watch For

Be skeptical of any provider or clinic that:

• Guarantees specific outcomes or uses terms like “miracle cure”
• Uses the same stem cell treatment for every condition, from autism to wrinkles
• Cannot explain exactly what cells they’re using, where the cells come from, or how they’re processed
• Discourages you from getting a second opinion or consulting your primary doctor
• Does not perform imaging-guided injections for orthopedic applications
• Charges upfront for multi-treatment packages at a significant discount
• Has no published research or institutional affiliation

Cost of Stem Cell Therapy

One of the biggest barriers to stem cell therapy is cost. In the United States, treatments are almost never covered by insurance, and prices vary widely.

Typical Price Ranges

• Bone marrow aspirate concentrate (BMAC) injection for a single joint: $3,000 to $8,000
• Adipose-derived stem cell therapy for a single joint: $4,000 to $10,000
• Umbilical cord tissue/Wharton’s jelly injection: $3,000 to $7,000 per injection
• Stem cell therapy for hair loss: $3,000 to $6,000 per session (often requires multiple sessions)
• Systemic IV stem cell infusion: $5,000 to $15,000, depending on the source and protocol
• Stem cell-augmented surgery (e.g., rotator cuff repair with BMAC): The stem cell component adds $2,000 to $5,000 to the surgical cost

Factors That Affect Cost

• Cell source: Autologous procedures (using your own cells) require harvesting and processing, which adds to the cost. Allogeneic (donor) products eliminate the harvest step but the products themselves can be expensive.
• Number of treatment areas: Treating multiple joints or sites in one session raises the price.
• Geographic location: Costs are generally higher in major metropolitan areas and on the coasts.
• Provider expertise and clinic overhead: Physicians with specialized training, published research, and advanced imaging capabilities often charge more.
• Follow-up care: Some clinics include follow-up imaging and physical therapy in the initial price; others charge separately.

Insurance Coverage

As of 2026, the vast majority of insurance plans, including Medicare, do not cover stem cell therapy for orthopedic or regenerative indications. There are limited exceptions for FDA-approved stem cell products used in specific contexts (e.g., hematopoietic stem cell transplants for blood cancers), but these are entirely different from the regenerative medicine applications discussed here.

Some patients use HSA/FSA funds to pay for treatment. A few clinics offer payment plans or financing through medical credit companies.

How to Choose a Stem Cell Therapy Provider

The difference between a good outcome and a bad one often comes down to who’s performing the procedure. Here’s how to evaluate a provider.

Credentials to Look For

• Board certification in a relevant specialty: orthopedic surgery, sports medicine, physical medicine and rehabilitation (PM&R), or interventional pain management
• Fellowship training in regenerative medicine or sports medicine
• Published research or active participation in clinical trials
• Membership in professional organizations such as the Interventional Orthopedics Foundation (IOF) or the American Academy of Regenerative Medicine

Questions to Ask Your Provider

Red Flags in a Provider

• No imaging guidance for injections
• Unable or unwilling to explain what’s in the product being injected
• Promises of guaranteed results
• No formal follow-up or outcome tracking
• A one-size-fits-all treatment approach
• Marketing that feels more like sales than medicine
• Staff rather than physicians performing the injections

A trustworthy provider will be transparent about what stem cell therapy can and cannot do. They’ll present realistic expectations, provide informed consent that includes a discussion of risks, and welcome your questions.

Stem Cell Therapy vs Other Regenerative Options

Stem cell therapy doesn’t exist in isolation. It’s part of a broader toolkit of regenerative and biologic treatments. Understanding how these options compare can help you make an informed decision.

PRP (Platelet-Rich Plasma)

PRP therapy concentrates the platelets and growth factors from your own blood and delivers them to the treatment site. PRP is simpler, less invasive, and significantly less expensive than stem cell therapy (typically $500 to $2,000 per injection). For mild to moderate conditions, PRP may be an excellent first step. Many clinicians use PRP before considering stem cells, reserving stem cell therapy for patients who need a more potent biologic stimulus or who haven’t responded adequately to PRP.

Prolotherapy

Prolotherapy involves injecting an irritant solution (usually dextrose) to stimulate a healing response. It’s the least expensive regenerative option and has a long track record for treating ligament laxity and chronic joint instability. Evidence quality is lower than for PRP or stem cells, but many patients report meaningful improvement. Prolotherapy may be appropriate for patients with mild conditions or budget constraints.

Exosome Therapy

Exosomes are tiny extracellular vesicles that carry growth factors, proteins, and RNA. They’re essentially the “messages” that stem cells send to other cells. Exosome therapy vs PRP is a growing area of comparison. The theoretical advantage of exosomes is that they may deliver the therapeutic benefits of stem cells without requiring actual living cells. However, exosome therapy is the least regulated and least studied of these options. The FDA has issued warnings about unapproved exosome products [20]. Until better evidence and regulatory clarity emerge, exosomes should be considered experimental.

How to Think About the Spectrum

A reasonable framework, and one many experienced regenerative medicine physicians use, looks like this:

• Mild to moderate conditions, first-line treatment: PRP
• Moderate conditions, failed PRP, or conditions needing a stronger stimulus: Stem cell therapy (BMAC or adipose-derived)
• Surgical augmentation: Stem cells added to the surgical procedure (e.g., rotator cuff repair + BMAC) [11]
• Systemic inflammatory or autoimmune conditions: Stem cell therapy (typically IV MSC infusion)

The right choice depends on the severity of your condition, your treatment goals, your budget, and your tolerance for procedures of varying invasiveness.

The Bottom Line

Stem cell therapy is real medicine with real science behind it. It’s also a field where hype frequently outruns evidence, and where unscrupulous providers prey on desperate patients.

Here’s what you can say with confidence based on the current evidence:

• MSCs are well-characterized cells with clearly demonstrated anti-inflammatory, immunomodulatory, and regenerative properties [1][2][3][8].
• For knee osteoarthritis, the evidence from randomized controlled trials supports meaningful improvements in pain, function, and possibly cartilage preservation [4][5][6][7][12].
• For conditions like rotator cuff repair augmentation and certain autoimmune diseases, the evidence is moderate and growing [11][16].
• For neurological conditions, cardiac disease, hair loss, and many other applications, the evidence is preliminary but worth watching.
• The field needs standardization in cell processing, dosing, delivery, and outcome measurement [9][10].

If you’re considering stem cell therapy, do your homework. Find a qualified provider with relevant credentials and a track record of transparency. Ask hard questions. Be wary of guarantees. And understand that while stem cell therapy may help you, it isn’t guaranteed to, and it isn’t cheap.

The most exciting thing about stem cell therapy isn’t what it can do today. It’s the trajectory. Every year brings better-designed trials, more refined techniques, and a clearer picture of which patients benefit most. In the coming decade, stem cell-based treatments will likely become more effective, more accessible, and more clearly defined by regulatory frameworks. For now, it’s a powerful option when applied appropriately by the right hands.

When to See a Doctor

You should consult a physician with regenerative medicine experience if:

• You have joint pain or osteoarthritis that hasn’t responded to physical therapy, weight management, injections (cortisone, hyaluronic acid), or activity modification
• You’re facing a joint replacement but want to explore alternatives or delay surgery
• You have a tendon or ligament injury that hasn’t healed with conservative treatment after three to six months
• You’re experiencing an autoimmune condition that’s poorly controlled on standard medications and are interested in investigational biologic approaches
• You want a second opinion on whether regenerative therapy might be appropriate for your specific situation

Do not attempt to self-treat with stem cell products purchased online or from unverified sources. Always work with a licensed physician who can properly evaluate your condition, discuss realistic outcomes, and perform the procedure safely.

Frequently Asked Questions

Does stem cell therapy work for knee osteoarthritis?

The best evidence is for mesenchymal stem cells (MSCs) in knee osteoarthritis. Multiple randomized controlled trials report meaningful reductions in pain and improvements in function, and some show possible cartilage preservation. Results vary by cell source, dose, and preparation, and long-term durability is still being studied. Evidence grade: promising, not yet established.

How much does stem cell therapy cost?

In the US, stem cell injections typically run about $5,000 to $20,000 or more per treatment, depending on the cell source, the number of joints treated, and the clinic. It is rarely covered by insurance because most uses are considered investigational. Be cautious of clinics whose pricing is not matched by published evidence for your condition.

Is stem cell therapy FDA approved?

Only a few stem cell products are FDA approved, mainly blood-forming (hematopoietic) stem cell transplants for certain cancers and blood disorders. The large majority of stem cell treatments marketed for orthopedic, anti-aging, or systemic conditions are not FDA approved and are offered as investigational. The FDA has issued public warnings about unapproved and unsafe stem cell products.

Is stem cell therapy safe?

For properly processed MSC injections performed by qualified providers, serious adverse events are uncommon and usually limited to temporary pain or swelling at the injection site. Risk rises sharply with unregulated clinics, non-standardized products, and unproven routes such as intravenous or intrathecal administration, which the FDA has linked to infections, tumors, and vision loss.

What is the difference between stem cell therapy and PRP?

PRP (platelet-rich plasma) concentrates growth factors from your own blood, while stem cell therapy uses living cells, usually mesenchymal stem cells from bone marrow, fat, or donor tissue. Stem cell preparations are more complex and expensive; PRP is cheaper and better studied for some uses. The two are sometimes combined in the same procedure.

How long does stem cell therapy take to work?

Stem cell therapy is not an instant fix. Patients who respond usually notice gradual changes over about 4 to 12 weeks as inflammation settles and tissue repair proceeds, with maximal benefit sometimes taking up to 6 months. If a clinic promises immediate or guaranteed results, treat that as a warning sign.

Which conditions have the strongest evidence for stem cell therapy?

The strongest evidence is for hematopoietic stem cell transplantation in blood cancers, an established therapy used for decades, and for MSCs in steroid-resistant graft-versus-host disease and knee osteoarthritis. Evidence for rotator cuff repair augmentation and some autoimmune conditions is emerging. Many other advertised uses remain unproven.

What are the red flags of a stem cell clinic to avoid?

Warning signs include guaranteed cures, treating many unrelated conditions with the same product, intravenous “stem cells” for systemic disease, no legitimate informed consent, refusal to specify the cell source or count, no qualified physician oversight, and prices unsupported by published evidence. Verify the provider, the product, and the evidence for your specific condition.

References

1. Pittenger MF et al. “Multilineage potential of adult human mesenchymal stem cells.” Science 1999;284(5411):143-147. PMID: 10102814
2. Caplan AI. “Mesenchymal stem cells: time to change the name!” Stem Cells Transl Med 2017;6(6):1445-1451. PMID: 28452204
3. Uccelli A et al. “Mesenchymal stem cells in health and disease.” Nat Rev Immunol 2008;8(9):726-736. PMID: 19172693
4. Jo CH et al. “Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee.” Stem Cells 2014;32(5):1254-1266. PMID: 24449146
5. Centeno CJ et al. “Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells.” Pain Physician 2008;11(3):343-353. PMID: 18523506
6. Vega A et al. “Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized controlled trial.” Transplantation 2015;99(8):1681-1690. PMID: 25822648
7. Koh YG et al. “Clinical results and second-look arthroscopic findings after treatment with adipose-derived stem cells for knee osteoarthritis.” KSSTA 2015;23(5):1308-1316. PMID: 24326779
8. Dominici M et al. “Minimal criteria for defining multipotent mesenchymal stromal cells.” Cytotherapy 2006;8(4):315-317. PMID: 16923606
9. Galipeau J, Sensebe L. “Mesenchymal stromal cells: clinical challenges and therapeutic opportunities.” Cell Stem Cell 2018;22(6):824-833. PMID: 29859173
10. Mautner K et al. “A call for a standard classification system for future biologic research.” PM&R 2015;7(4 Suppl):S53-S59. PMID: 25864661
11. Hernigou P et al. “Biologic augmentation of rotator cuff repair with mesenchymal stem cells.” Int Orthop 2014;38(9):1811-1818. PMID: 24913770
12. Pas HI et al. “Stem cell injections in knee osteoarthritis: a systematic review.” BJSM 2017;51(15):1125-1133. PMID: 28258177
13. Orozco L et al. “Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study.” Transplantation 2011;92(7):822-828. PMID: 21792091
14. Uccelli A et al. “MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.” Trials 2019;20(1):263. PMID: 31072380
15. Vaquero J et al. “Intrathecal administration of autologous mesenchymal stromal cells for spinal cord injury: safety and efficacy of the 100/3 guideline.” Cytotherapy 2018;20(6):806-819. PMID: 29853256
16. Le Blanc K et al. “Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.” Lancet 2008;371(9624):1579-1586. PMID: 18468541
17. Fisher SA et al. “Stem cell therapy for chronic ischaemic heart disease and congestive heart failure.” Cochrane Database Syst Rev 2014;(4):CD007888. PMID: 24777540
18. Gentile P et al. “The effect of platelet-rich plasma in hair regrowth: a randomized placebo-controlled trial.” Stem Cells Transl Med 2015;4(11):1317-1323. PMID: 26400925
19. Marks PW et al. “Clarifying stem-cell therapy’s benefits and risks.” N Engl J Med 2017;376(11):1007-1009. PMID: 27959704
20. US Food and Drug Administration. “FDA warns about stem cell therapies.” FDA Safety Communication. 2019. Available at: https://www.fda.gov/consumers/consumer-updates/fda-warns-about-stem-cell-therapies

About the medical reviewer

Dr. Bronwyn Holmes, MD, FAARFM is a physician specialising in regenerative medicine, advanced peptide therapeutics, exosome and stem cell biology, hormonal health, and longevity. Last reviewed July 5, 2026.